What does Ziphius do?

Ziphius is a research organisation in Gent. Public Limited, started on 10 July 2020, 1 establishment.

What is the address of Ziphius?

The registered office of Ziphius is located at Rijvisschestraat 120, 9052 Gent.

Is Ziphius still active?

Yes. According to the CBE (29 October 2026) Ziphius is active, legal situation “Normale toestand”, started on 10 July 2020.

Is Ziphius registered on Peppol?

Yes, Ziphius is registered on the Peppol network with ID 0208:0750500975.

What is the enterprise number of Ziphius?

The enterprise number of Ziphius is BE0750500975.

When was Ziphius founded?

Ziphius was founded on 10 July 2020.

Who are the directors of Ziphius?

According to the 2025 annual accounts, the directors of Ziphius are: Margareta Nuytinck, Van Hoof Biotech and Business Services BV, JOB.BIO.COM BV, Olem SRL, Geertrui Vanhove, CARDON BIO NV, Heran BV.

Is Ziphius a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 10 July 2020; 4 annual accounts filed, latest fiscal year 2025; 7 directors known from the annual account.

How much profit did Ziphius make in 2025?

Ziphius recorded a loss after taxes of € 11,759,972 in financial year 2025.

What is the revenue of Ziphius?

As a small company, Ziphius is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 2,432,075.

How much does an employee at Ziphius earn?

The average wage cost per full-time employee at Ziphius was € 90,500 in 2025: staff costs of € 3.7 million for 41.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Ziphius have?

According to the 2025 annual accounts, Ziphius has 41.2 full-time equivalents (FTE).

Ziphius (Public Limited) - Gent - BE0750500975

Dossier Ziphius, printed on 29 October 2026 from databakkes.be/en/0750500975/ziphius. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2023 and 2025.
Tight liquidity NBB

Cash and receivables cover 55 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Ziphius from Gent, company number BE0750500975, closed financial year 2025 with a result of € -11.8 million after tax. For that financial year Ziphius recorded a gross margin of € 2.4 million and equity of € 5.9 million. Compared with financial year 2023, the result moved from € -10.7 million to € -11.8 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 26, 2026.

What it is worth Healthy

€ 5.9 million

▼ 19% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -11.8 million

▼ 10 % more loss than in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 733,828

▼ 86% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -10.6 million.

People and assets in 2025

Full-time equivalents

41.2

▼ 1.1 vs 2023

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 3.7 million

▲ 9% vs 2023

€ 90,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1.4 million

▼ 43% vs 2023

Of which on lease € 1.4 million.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.9 million

▼ 74% vs 2023

€ 481,860 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 1.2 million

▼ 26% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 352,787

▼ 34% vs 2023

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2025	Change 2023 → 2025
Gross margin	€ -2,207,142 Gross margin 2021: € -2,207,142 First fiscal year in the series	€ -3,249,115 Gross margin 2022: € -3,249,115 ▼ € 1 million vs 2021 (€ -2,207,142) Unfavourable step	€ 1,438,368 Gross margin 2023: € 1,438,368 ▲ € 4.7 million vs 2022 (€ -3,249,115) Favourable step	€ 2,432,075 Gross margin 2025: € 2,432,075 ▲ 69% vs 2023 (€ 1,438,368) Favourable step	▲ 69%
Profit after taxes	€ -3,751,415 Profit after taxes 2021: € -3,751,415 First fiscal year in the series	€ -5,646,726 Profit after taxes 2022: € -5,646,726 ▼ € 1.9 million vs 2021 (€ -3,751,415) Unfavourable step	€ -10,687,769 Profit after taxes 2023: € -10,687,769 ▼ € 5 million vs 2022 (€ -5,646,726) Unfavourable step	€ -11,759,972 Profit after taxes 2025: € -11,759,972 ▼ € 1.1 million vs 2023 (€ -10,687,769) Unfavourable step	▼ € 1.1 million
Equity	€ 23,522,785 Equity 2021: € 23,522,785 First fiscal year in the series	€ 18,008,310 Equity 2022: € 18,008,310 ▼ 23% vs 2021 (€ 23,522,785) Unfavourable step	€ 7,320,540 Equity 2023: € 7,320,540 ▼ 59% vs 2022 (€ 18,008,310) Unfavourable step	€ 5,900,140 Equity 2025: € 5,900,140 ▼ 19% vs 2023 (€ 7,320,540) Unfavourable step	▼ 19%
Total debts	€ 2,816,860 Total debts 2021: € 2,816,860 First fiscal year in the series	€ 3,189,173 Total debts 2022: € 3,189,173 ▲ 13% vs 2021 (€ 2,816,860) Unfavourable step	€ 10,898,732 Total debts 2023: € 10,898,732 ▲ 242% vs 2022 (€ 3,189,173) Unfavourable step	€ 3,594,022 Total debts 2025: € 3,594,022 ▼ 67% vs 2023 (€ 10,898,732) Favourable step	▼ 67%
Cash	€ 22,956,151 Cash 2021: € 22,956,151 First fiscal year in the series	€ 6,530,432 Cash 2022: € 6,530,432 ▼ 72% vs 2021 (€ 22,956,151) Unfavourable step	€ 5,071,242 Cash 2023: € 5,071,242 ▼ 22% vs 2022 (€ 6,530,432) Unfavourable step	€ 733,828 Cash 2025: € 733,828 ▼ 86% vs 2023 (€ 5,071,242) Unfavourable step	▼ 86%
Retained profit	€ -3,751,415 Retained profit 2021: € -3,751,415 First fiscal year in the series	€ -9,398,140 Retained profit 2022: € -9,398,140 ▼ € 5.6 million vs 2021 (€ -3,751,415) Unfavourable step	€ -19,953,660 Retained profit 2023: € -19,953,660 ▼ € 10.6 million vs 2022 (€ -9,398,140) Unfavourable step	€ -10,627,396 Retained profit 2025: € -10,627,396 ▲ € 9.3 million vs 2023 (€ -19,953,660) Favourable step	▲ € 9.3 million
Bank debt	€ 1,897,251 Bank debt 2021: € 1,897,251 First fiscal year in the series	€ 1,680,346 Bank debt 2022: € 1,680,346 ▼ 11% vs 2021 (€ 1,897,251) Favourable step	€ 7,143,320 Bank debt 2023: € 7,143,320 ▲ € 5.5 million vs 2022 (€ 1,680,346) Unfavourable step	€ 1,868,299 Bank debt 2025: € 1,868,299 ▼ 74% vs 2023 (€ 7,143,320) Favourable step	▼ 74%
Balance sheet total	€ 26,339,646 Balance sheet total 2021: € 26,339,646 First fiscal year in the series	€ 21,197,483 Balance sheet total 2022: € 21,197,483 ▼ 20% vs 2021 (€ 26,339,646) Unchanged	€ 18,219,273 Balance sheet total 2023: € 18,219,273 ▼ 14% vs 2022 (€ 21,197,483) Unchanged	€ 9,494,162 Balance sheet total 2025: € 9,494,162 ▼ 48% vs 2023 (€ 18,219,273) Unchanged	▼ 48%
Employees (FTE)	16.5 Employees (FTE) 2021: 16.5 First fiscal year in the series	30.5 Employees (FTE) 2022: 30.5 ▲ 14 vs 2021 (16.5) Unchanged	42.3 Employees (FTE) 2023: 42.3 ▲ 11.8 vs 2022 (30.5) Unchanged	41.2 Employees (FTE) 2025: 41.2 ▼ 1.1 vs 2023 (42.3) Unchanged	▼ 1.1

Key figures of Ziphius, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Ziphius?

What happened at Ziphius in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 Margareta Nuytinck stepped down as director. NBB
2027 Van Hoof Biotech and Business Services BV stepped down as director. NBB
2027 JOB.BIO.COM BV stepped down as director. NBB
2027 Olem SRL stepped down as director. NBB
2027 Geertrui Vanhove stepped down as director. NBB
2027 CARDON BIO NV stepped down as director. NBB
2027 Heran BV stepped down as director. NBB
May 26, 2026 New annual accounts for financial year 2025: loss of € 11.8 million. Source: NBB ↗

In short

From € 3.8 million loss in 2021 to € 11.8 million loss in 2025.

Paid € 2,199 in corporate taxes since 2021.

On average € 59,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

RNA Pioneering 59%

CEBELEC 15%

The stake of RNA Pioneering, CEBELEC comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Ziphius

Ziphius LLC 100%

The shares are held by RNA Pioneering (59%) and CEBELEC (15%). It owns 100% of Ziphius LLC itself.

Directors

According to the 2025 annual accounts

Margareta Nuytinck

Director

Also active at: LABORATORIUM M. NUYTINCK, QUOD BONUM, FELIX FAUSTUMQUE SIT, LABO VOOR KLINISCHE BIOLOGIE, POST VERBA VERBERA, ANABIOTEC, MENTANA DX, ERGO TUA RURA MANEBUNT

since 2024 · until 2030

Van Hoof Biotech and Business Services BV

Director · represented by Johan Van Hoof

since 2023 · until 2027

JOB.BIO.COM BV

Director · represented by Johan Bury

since 2024 · until 2027

Olem SRL

Director · represented by Olivier Lemaire

since 2021 · until 2027

Geertrui Vanhove

Director

since 2024 · until 2027

CARDON BIO NV

Managing director · represented by Christiaan Cardon

since 2024 · until 2027

Heran BV

Director · represented by Annie Vereecken

Also active at: ALLEGRO

since 2021 · until 2027

Shareholders

RNA Pioneering

59%

CEBELEC

15%

Participations

Ziphius LLC

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Rijvisschestraat 120

9052 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.

All companies at this address →

RNA Pioneering same network

€ -111,461 gross margin · 2025

DOING WELL BY DOING GOOD

€ 27,550 gross margin · 2025

CARDON BIO same network

€ 25,626 gross margin · 2025

CELL-CELL BIO

€ 777,487 gross margin · 2025

BORDEAUX I

€ -3,685 gross margin · 2025

+1 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0750.500.975

VAT number

BE 0750.500.975

Registered office

Rijvisschestraat 120, 9052 Gent

Names & denominations

Ziphius

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

10 July 2020

Peppol

Active · Active since 27 Mar 2026

Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Vervaardiging van geneesmiddelen

View on CBE Public ↗ Annual accounts (NBB) ↗

Ziphius

Warning lights

Financials

What happened to Ziphius?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions